338
Participants
Start Date
September 30, 2005
Study Completion Date
August 31, 2007
SB-773812
Olanzapine
GSK Investigational Site, Liège
GSK Investigational Site, Montignies-sur-Sambre
GSK Investigational Site, Orangeburg
GSK Investigational Site, Washington D.C.
GSK Investigational Site, Falls Church
GSK Investigational Site, Butner
GSK Investigational Site, North Miami
GSK Investigational Site, Birmingham
GSK Investigational Site, Cincinnati
GSK Investigational Site, Bellaire
GSK Investigational Site, San Antonio
GSK Investigational Site, Albuquerque
GSK Investigational Site, Cerritos
GSK Investigational Site, Upland
GSK Investigational Site, National City
GSK Investigational Site, San Diego
GSK Investigational Site, Garden Grove
GSK Investigational Site, Moscow
GSK Investigational Site, Moscow
GSK Investigational Site, Moscow
GSK Investigational Site, Ludhiana
GSK Investigational Site, Leningraskaya Region
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Lucknow
GSK Investigational Site, Ahmedabad
GSK Investigational Site, Pune
GSK Investigational Site, Tirupati
GSK Investigational Site, Bangalore
GSK Investigational Site, Bangalore
GSK Investigational Site, Bangalore
GSK Investigational Site, Mangalore
GSK Investigational Site, Nizhny Novgorod
GSK Investigational Site, New Haven
GSK Investigational Site, Clementon
GSK Investigational Site, Kenilworth
GSK Investigational Site, San José
GSK Investigational Site, Lnáře
GSK Investigational Site, Lima
GSK Investigational Site, Brno
GSK Investigational Site, Prague
GSK Investigational Site, Hyderabad
GSK Investigational Site, Smolensk
Lead Sponsor
GlaxoSmithKline
INDUSTRY